mobile menu button
A+ -A Français Make a Payment
Search Arrow

Somatic Tumour Profiling


Make confident treatment decisions based on the entire tumour profile 

From a single tumour biopsy, analyzed by advanced NGS technology, OmniSeq INSIGHT identifies treatment options in one comprehensive, easy-to-read report. The patient report delivers complete INSIGHT into the tumor and its microenvironment by summarizing FDA-approved therapies, immunotherapies and eligible clinical trials for your patient’s solid tumour.

A consolidated assay for two different treatment paradigms:

Genomic profiling:
• 523 gene NGS panel
• MSl and TMB*
• DNA and RNA sequencing
• SNVs, indels, CNAs and fusions*
• Interrogation of fuII coding regions 

Immune profiling
• PD-L1 immunohistochemistry (IHC)
• 64 RNA expression/immune profiling genes by immune cycle step:
• T-cell priming/trafficking
• T-cell recognition
• T-cell infiltration
• Killing cancer cells
• Cancer testis antigens

INSIGHT is the only comprehensive test to contain all of the following:
• Genes aligned with FDA approvals, professional practice guidelines and clinical trials
• HRR/HRD-related* genes for PARP therapeutic selection
• Full coding region coverage for each gene which improves variant detection compared to “hotspot” testing strategies
• An RNA-seq hybrid capture approach which allows for the detection of common and novel fusions
• Targeting of unique emerging and actionable markers
• Immune gene expression (mRNA) analysis to evaluate the interaction between the tumour and its microenvironment

INSIGHT may be useful as a tool in various clinical settings, including:
• When guidelines recommend broad genomic profiling to evaluate genes with clinical evidence and therapeutic recommendations or when standard biomarker evaluation yields no targeted therapeutic option
• When a broad genomic profile identifies treatment options in clinical trials including immunotherapies and targeted therapies for patient enrollment
• When a cancer lacks an effective standard-of-care therapy at the time of diagnosis or when a tumour is poorly differentiated and of uncertain origin
• When relapse or disease progression has occurred prior therapies

Download OmniSeq Insight Brochure
Download OmniSeq Insight Gene List
Download OmniSeq Insight Requisition
Download OmniSeq Insight Payment Authorization Form
Download OmniSeq Specimen Instructions and Packing Sheet